Peter Turner appointed to NPS MedicineWise Board

NPS MedicineWise has welcomed Mr Peter Turner to its Board in the position of Additional Director effective 9 December 2012.

Chair of NPS MedicineWise Dr Janette Randall says that with over 40 years experience in the biopharmaceutical industry, Mr Turner will bring vast experience from both domestic and international appointments.

Having worked in Europe and the United States as well as having extensive experience in Australian industry, his expertise includes international healthcare, managing global business expansion, blood plasma therapies, protein separation technologies, pharmaceutical product development and quality assurance and industrial scale biotechnology.

He is a past Chairman and board member of the PPTA (Plasma Protein Therapeutics Association) and is a member of the Australian Institute of Company Directors.

Mr Turner says that having had the opportunity during his career to observe healthcare services throughout the world, it is clear that access to medicines and treatment is an increasing challenge for society.

“The comprehensive work of NPS impressed me as a rational way to make superior choices in the use of medicines,” he said.

Mr Turner replaces Mr Russell Edwards who is retiring at the end of 2012 having served on the Board since December 2006 and chaired the NPS Audit Committee since October 2007.

“Russell brought senior experience of the medicines industry to the NPS Board, and we greatly value the insights he shared with us over the past five years,” said Dr Randall.

“I’d like to thank Russell for his contribution to the Board, and in particular for his leadership on the NPS Audit Committee which he chaired from October 2007 – July 2012.”


Independent, evidence-based and not-for-profit, NPS MedicineWise enables better decisions about medicines and medical tests. We are funded by the Australian Government Department of Health and Ageing.